Molecular Cancer Therapeutics: 11 (7)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther July 1 2012 11 (7) 1383-1383;

Spotlight on Clinical Response

Spotlight on Clinical Response

Early FDG/PET Scanning as a Pharmacodynamic Marker of Anti-EGFR Antibody Activity in Colorectal Cancer

Geoffrey W. Krystal, Erin Alesi and James L. Tatum

Mol Cancer Ther July 1 2012 11 (7) 1385-1388; DOI:10.1158/1535-7163.MCT-12-0011

Therapeutic Discovery

Therapeutic Discovery

Inducible Silencing of Protein Kinase D3 Inhibits Secretion of Tumor-Promoting Factors in Prostate Cancer

Courtney R. LaValle, Liyong Zhang, Shuping Xu, Julie L. Eiseman and Q. Jane Wang

Mol Cancer Ther July 1 2012 11 (7) 1389-1399; DOI:10.1158/1535-7163.MCT-11-0887
Therapeutic Discovery

Human Monoclonal Antibodies Targeting Nonoverlapping Epitopes on Insulin-like Growth Factor II as a Novel Type of Candidate Cancer Therapeutics

Weizao Chen, Yang Feng, Qi Zhao, Zhongyu Zhu and Dimiter S. Dimitrov

Mol Cancer Ther July 1 2012 11 (7) 1400-1410; DOI:10.1158/1535-7163.MCT-12-0172
Therapeutic Discovery

ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo

Pamela K. Foreman, Medini Gore, Philip A. Kobel, Li Xu, Helena Yee, Charles Hannum, Hoangdung Ho, Sandra M. Wang, Hieu V. Tran, Michael Horowitz, Lawrence Horowitz and Ramesh R. Bhatt

Mol Cancer Ther July 1 2012 11 (7) 1411-1420; DOI:10.1158/1535-7163.MCT-12-0068
Therapeutic Discovery

Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer

Xinyi Liu, Indira Jutooru, Ping Lei, KyoungHyun Kim, Syng-ook Lee, Lisa K. Brents, Paul L. Prather and Stephen Safe

Mol Cancer Ther July 1 2012 11 (7) 1421-1431; DOI:10.1158/1535-7163.MCT-12-0026
Therapeutic Discovery

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano III, Laura T. Pierce, Melissa Farwell, Douglas W. McMillin, Antoaneta Necheva, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson and Margaret S. Lee

Mol Cancer Ther July 1 2012 11 (7) 1432-1442; DOI:10.1158/1535-7163.MCT-11-0925
Therapeutic Discovery

Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents In Vitro and In Vivo

Hui-Chun Wang, Alan Yueh-Luen Lee, Wen-Cheng Chou, Chin-Chung Wu, Chao-Neng Tseng, Kevin Yen-Ting Liu, Wen-Lien Lin, Fang-Rong Chang, Da-Wei Chuang, Attila Hunyadi and Yang-Chang Wu

Mol Cancer Ther July 1 2012 11 (7) 1443-1453; DOI:10.1158/1535-7163.MCT-11-0921
Therapeutic Discovery

microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells

Huanyu Zhang, Meng Qi, Shiwang Li, Teng Qi, Hong Mei, Kai Huang, Liduan Zheng and Qiangsong Tong

Mol Cancer Ther July 1 2012 11 (7) 1454-1466; DOI:10.1158/1535-7163.MCT-12-0001
Therapeutic Discovery

Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies

Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou, Jianlong Lou, Fraser Conrad, Gregory P. Adams, Birgit Schoeberl, Ulrik B. Nielsen and James D. Marks

Mol Cancer Ther July 1 2012 11 (7) 1467-1476; DOI:10.1158/1535-7163.MCT-11-1038
Therapeutic Discovery | Free Article

Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps

John C. Zwaagstra, Traian Sulea, Jason Baardsnes, Anne E.G. Lenferink, Cathy Collins, Christiane Cantin, Béatrice Paul-Roc, Suzanne Grothe, Sazzad Hossain, Louis-Philippe Richer, Denis L'Abbé, Roseanne Tom, Brian Cass, Yves Durocher and Maureen D. O'Connor-McCourt

Mol Cancer Ther July 1 2012 11 (7) 1477-1487; DOI:10.1158/1535-7163.MCT-12-0060

Preclinical Development

Preclinical Development

Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells

C. Elizabeth Caldon, C. Marcelo Sergio, Jian Kang, Anita Muthukaruppan, Marijke N. Boersma, Andrew Stone, Jane Barraclough, Christine S. Lee, Michael A. Black, Lance D. Miller, Julia M. Gee, Rob I. Nicholson, Robert L. Sutherland, Cristin G. Print and Elizabeth A. Musgrove

Mol Cancer Ther July 1 2012 11 (7) 1488-1499; DOI:10.1158/1535-7163.MCT-11-0963
Preclinical Development

Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer

Mickey K. Kim, Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, Bryan M. Clary, Timothy Clay, Michael A. Morse, Philip G. Febbo, H. Kim Lyerly and David S. Hsu

Mol Cancer Ther July 1 2012 11 (7) 1500-1509; DOI:10.1158/1535-7163.MCT-11-0937
Preclinical Development

Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells

Peter B. Makhov, Konstantin Golovine, Alexander Kutikov, Ervin Teper, Daniel J. Canter, Jay Simhan, Robert G. Uzzo and Vladimir M. Kolenko

Mol Cancer Ther July 1 2012 11 (7) 1510-1517; DOI:10.1158/1535-7163.MCT-11-0907
Preclinical Development

XIAP Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells

Jennifer L. Allensworth, Katherine M. Aird, Amy J. Aldrich, Ines Batinic-Haberle and Gayathri R. Devi

Mol Cancer Ther July 1 2012 11 (7) 1518-1527; DOI:10.1158/1535-7163.MCT-11-0787
Preclinical Development

Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas

Giuliana Cavalloni, Caterina Peraldo-Neia, Ivana Sarotto, Loretta Gammaitoni, Giorgia Migliardi, Marco Soster, Serena Marchiò, Massimo Aglietta and Francesco Leone

Mol Cancer Ther July 1 2012 11 (7) 1528-1538; DOI:10.1158/1535-7163.MCT-11-1020
Preclinical Development

Effect of a Low-Fat Diet Combined with IGF-1 Receptor Blockade on 22Rv1 Prostate Cancer Xenografts

Ramdev Konijeti, Satomi Koyama, Ashley Gray, R. James Barnard, Jonathan W. Said, Brandon Castor, David Elashoff, Junxiang Wan, Pedro J. Beltran, Frank J. Calzone, Pinchas Cohen, Colette Galet and William J. Aronson

Mol Cancer Ther July 1 2012 11 (7) 1539-1546; DOI:10.1158/1535-7163.MCT-11-1003
Preclinical Development

Thermal Targeting of an Acid-Sensitive Doxorubicin Conjugate of Elastin-like Polypeptide Enhances the Therapeutic Efficacy Compared with the Parent Compound In Vivo

Shama Moktan, Eddie Perkins, Felix Kratz and Drazen Raucher

Mol Cancer Ther July 1 2012 11 (7) 1547-1556; DOI:10.1158/1535-7163.MCT-11-0998
Preclinical Development

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

Wataru Okamoto, Isamu Okamoto, Tokuzo Arao, Kiyoko Kuwata, Erina Hatashita, Haruka Yamaguchi, Kazuko Sakai, Kazuyoshi Yanagihara, Kazuto Nishio and Kazuhiko Nakagawa

Mol Cancer Ther July 1 2012 11 (7) 1557-1564; DOI:10.1158/1535-7163.MCT-11-0934
Preclinical Development | Free Article

Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia

Jeremy B. Samon, Mireia Castillo-Martin, Michael Hadler, Alberto Ambesi-Impiobato, Elisabeth Paietta, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, John Jakubczak, Sophia Randolph, Carlos Cordon-Cardo and Adolfo A. Ferrando

Mol Cancer Ther July 1 2012 11 (7) 1565-1575; DOI:10.1158/1535-7163.MCT-11-0938
Preclinical Development

Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer

Minghai Shao, Stacy Hollar, Daphne Chambliss, Jordan Schmitt, Robert Emerson, Bhadrani Chelladurai, Susan Perkins, Mircea Ivan and Daniela Matei

Mol Cancer Ther July 1 2012 11 (7) 1576-1586; DOI:10.1158/1535-7163.MCT-11-0961
Preclinical Development

Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer

Adam D. Steg, Ashwini A. Katre, Kerri S. Bevis, Angela Ziebarth, Zachary C. Dobbin, Monjri M. Shah, Ronald D. Alvarez and Charles N. Landen

Mol Cancer Ther July 1 2012 11 (7) 1587-1597; DOI:10.1158/1535-7163.MCT-11-1058
Preclinical Development

CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis

Dharmalingam Subramaniam, Giridharan Periyasamy, Sivapriya Ponnurangam, Debarshi Chakrabarti, Aravind Sugumar, Muralidhara Padigaru, Scott J. Weir, Arun Balakrishnan, Somesh Sharma and Shrikant Anant

Mol Cancer Ther July 1 2012 11 (7) 1598-1608; DOI:10.1158/1535-7163.MCT-12-0102

Molecular Medicine in Practice

Molecular Medicine in Practice

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

Craig P. Carden, Adam Stewart, Parames Thavasu, Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B Kaye and Udai Banerji

Mol Cancer Ther July 1 2012 11 (7) 1609-1617; DOI:10.1158/1535-7163.MCT-11-0996

Main menu

User menu

Search

Table of Contents

Highlights

Spotlight on Clinical Response

Therapeutic Discovery

Preclinical Development

Molecular Medicine in Practice

Issue Highlights

Jump to

Articles

Info for

About MCT